Trials / Completed
CompletedNCT05633953
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
A Retrospective Observational Study to Evaluate the Safety and Effectiveness of Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome (LINC7)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 103 (actual)
- Sponsor
- RECORDATI GROUP · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-CD CS patients. Patients treated with oral osilodrostat regardless of the duration of their treatment will be followed retrospectively for up to 36 months after initiating osilodrostat.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Osilodrostat | oral administration |
Timeline
- Start date
- 2023-01-16
- Primary completion
- 2023-09-30
- Completion
- 2023-10-30
- First posted
- 2022-12-01
- Last updated
- 2025-02-10
- Results posted
- 2025-02-10
Locations
1 site across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05633953. Inclusion in this directory is not an endorsement.